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AIDS in Africa
SUMMARY
Sub-Saharan Africa has been far more
severely affected by AIDS than any other part
of the world.  The United Nations reports that
28.1 million adults and children are infected
with the HIV virus in the region, which has
about 10% of the world’s population but more
than 70% of the worldwide total of infected
people.  The overall rate of infection among
adults in sub-Saharan Africa is about 8.4%; it
is 1.2% worldwide.  Sixteen countries, mostly
in eastern and southern Africa, have HIV
infection rates of more than 10%, and the rate
has reached 35.8% in Botswana.  An estimated
19.3 million Africans have died from AIDS,
including 2.3 million who died in 2001.  AIDS
has surpassed malaria as the leading cause of
death in Africa, and it kills many times more
Africans than war.  In Africa, HIV is spread
primarily by heterosexual contact, and sub-
Saharan Africa is the only region where
women are infected at a higher rate than men.
Experts relate the severity of the African
AIDS epidemic to the region’s poverty.
Health systems are ill-equipped for prevention,
diagnosis, and treatment.  Poverty forces many
men to become migrant workers in urban
areas, where they may have multiple sex part-
ners. Poverty leads many women to become
commercial sex workers, vastly increasing
their risk of infection. 
AIDS’ social and economic consequences
are severe, depriving Africa of skilled workers
and teachers while reducing life expectancy by
decades in some countries.  The cumulative
total of African children orphaned by AIDS
since the epidemic began is 12.1 million.
Currently 6.5 million AIDS orphans are living
in Africa, facing increased risk of malnutrition
and reduced prospects for education.  AIDS is
being blamed for declines in agricultural pro-
duction in some countries.
Donor governments, non-governmental
organizations, and African governments have
responded  primarily by attempting to reduce
the number of new HIV infections, and by
trying ameliorate the damage done by AIDS to
families, societies, and economies.  The ade-
quacy of this response is the subject of much
debate.  Spending from all sources on HIV/-
AIDS in sub-Saharan Africa was estimated at
$500 million for FY2000, while U.N. experts
believe the region could effectively absorb
$4.6 billion to combat the pandemic.
Treatment of AIDS sufferers with medi-
cines that can result in long-term survival  has
not been widely used in Africa.  Advocates of
treatment argue that in view of recent drug
price reductions, treatment is an affordable
means of  reducing AIDS damage to  African
economies, reinforcing prevention programs,
and keeping parents alive.  Skeptics argue that
treatment is still too expensive to be an option
for most Africans and would require donors to
fund costly improvements in Africa’s health
infrastructure. 
U.S. concern over AIDS in Africa grew
during the 1980s, as the severity of the epi-
demic became apparent.  According to the
U.S. Agency for International Development,
the United States has been the global leader in
the international response to AIDS since 1986.
Legislation enacted in the 106th and the 107th
Congresses increased funding for worldwide
HIV/AIDS programs, and the Administration
has requested a further increase for FY2003.
The United States has also pledged $500
million to the new Global Fund to Fight AIDS,
Tuberculosis, and Malaria.  Nonetheless,
critics find the U.S. response inadequate in




On April 4, 2002, South Africa’s Constitutional Court ruled that the South African
government must provide the antiretroviral drug Nevirapine to HIV positive pregnant women
to prevent the transmission of the HIV to their babies.  The government is appealing an
earlier court order to provide the treatment but cannot delay complying while the appeals
process is underway, according to the Constitutional Court.  Also on April 4, Health and
Human Services Secretary Tommy Thompson said the United States would continue to help
South Africans fight the HIV/AIDS pandemic despite some differences with the South African
government over AIDS policy.  Secretary Thompson, while on a four-nation Africa tour,
pledged $30 million for AIDS and health related programs in Mozambique.  The Global
Fund to Fight AIDS, Tuberculosis, and Malaria reported on March 25 that it had received
grant applications for projects totaling $1.15 billion in 2002 but had just $700-$800 million
to award.  On March 24, Senator Jesse Helms wrote in a Washington Post op-ed article that
he and Senator Bill Frist would offer an amendment to the Administration-proposed
emergency supplemental appropriations to add $500 million in foreign assistance for
fighting mother-to-child transmission of HIV.  The amendment would require matching
contributions from the private sector. 
BACKGROUND AND ANALYSIS
Sub-Saharan Africa has been far more severely affected by AIDS than any other part of
the world.  According to a December 1, 2001 report issued by the Joint United Nations
Program on HIV/AIDS (UNAIDS), some 28.1 million adults and children are infected with
the HIV virus in the region, which has about 10% of the world’s population but 70% of the
worldwide total of infected people.  The overall rate of infection among adults is about 8.4%,
compared with 1.2% worldwide.  UNAIDS projects that half or more of all 15 year-olds will
eventually die of AIDS in some of the worst-affected countries, such as Zambia, South Africa,
and Botswana, unless the risk of contracting the disease is sharply reduced.   An estimated
19.3 million Africans have lost their lives to AIDS, including an estimated 2.3 million who
died in 2001.  UNAIDS estimates that 3.4 million new HIV infections occurred in 2001,
down from the estimated 3.8 million new infections in 2000.  Experts are cautious  in
suggesting that this decline might represent some success in prevention efforts, particularly
since the adult infection rates continue to increase in a number of countries, including Nigeria,
Africa’s most populous nation.  Moreover, they point out that 3.4 million new infections still
represents a very fast and highly destructive rate of spread.   AIDS has surpassed malaria as
the leading cause of death in sub-Saharan Africa, and it kills many times more people than
Africa’s armed conflicts.
Characteristics of the African Epidemic




! HIV, the human immunodeficiency virus that causes AIDS, is spread in
Africa primarily by heterosexual contact.
! Sub-Saharan Africa is the only region in which women are infected with HIV
at a higher rate than men.  According to UNAIDS, women make up an
estimated 55% of the HIV-positive adult population in sub-Saharan Africa,
as compared with 47% worldwide.
! Young women are particularly at risk.   A U.N. study found girls aged 15-19
to be infected at a rate of 15% to 23%, while infection rates among boys of
the same age were 3% to 4%.
! Eastern and southern Africa have been far more severely affected than West
Africa, but infection rates in a number of West African countries are starting
to escalate. In some southern African countries, 20% or more of the adult
population is infected with HIV, and the rate has reached 35.8% in
Botswana.  On March 20, 2001, the South African government released
statistics showing that 4.7 million South Africans, including 24.5% of adults,
were infected in 2000 – up from 22.4% in 1999.  In West Africa, Senegal,
with an active AIDS policy, had an adult infection rate below 2% in 1999,
but the infection rate exceeds 10% in nearby Ivory Coast. Adult infection
rates in four other West African countries, including Nigeria, have passed the
5% mark.
! The African AIDS epidemic is having a much greater impact on children than
is the case in other parts of the world.  An estimated 600,000 African infants
become infected with HIV each year through mother-to-child transmission,
either at birth or through breast-feeding. (White House, Report on the
Presidential Mission on Children Orphaned by AIDS in Sub-Saharan
Africa: Findings and Plan of Action.  Washington, July 19, 1999, p. 14.) 
These children have a short life expectancy, and the number of infected
children currently alive in Africa is estimated at 1 million (UNAIDS).
! A cumulative total of 12.1 million African AIDS orphans have lost either
their mother or both parents to AIDS since the epidemic began, according
to UNAIDS.  A report by the U.S. Agency for International Development
(USAID) puts the number of such orphans currently living in 26 African
countries at 6.5 million, and projects that by 2010, there will be 15 million
African AIDS orphans, including 2.7 million in Nigeria, 2.5 million in
Ethiopia, and 1.8 million in South Africa.  (Children on the Brink, 2000
update.)  Because of the stigma attached to the AIDS disease, AIDS orphans
run a greater risk of being malnourished, abused, and denied an education.
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Uganda   8.30
Tanzania   8.09
Cameroon   7.73
Burkina Faso   6.44
Congo Brazzaville   6.43
Togo   5.98
Congo Kinshasa     5.07
Nigeria   5.06
Gabon   4.16
Ghana   3.60
Sierra Leone   2.99
Eritrea   2.87
Liberia   2.80
Angola   2.78
Chad     2.69
Guinea Bissau   2.50
Benin   2.45
Mali             2.03
Gambia   1.95
Senegal   1.77
Guinea   1.54
Sudan     .99
Mauritania     .52
Equatorial Guinea     .51
Somalia     NA
Madagascar     .15
Source: UNAIDS, Report on the Global
HIV/AIDS Epidemic, June 2000
Explaining the African Epidemic
AIDS experts emphasize a variety of
economic and social factors in explaining Africa’s
AIDS epidemic, placing primary blame on the
region’s poverty.  Poverty has deprived Africa, for
example, of effective systems of health
information, health education, and health care.
Thus,  Africans suffer from a high rate of
untreated sexually-transmitted infections (STIs)
other than AIDS, and these increase susceptibility
to HIV.  African health care systems are typically
unable to provide AIDS counseling, which could
help slow the spread of the disease, and  even
HIV testing is difficult for many Africans to
obtain.  AIDS treatment is generally available only
to the elite.
Poverty forces large numbers of African men
to migrate long distances in search of work, and
while away from home they may have multiple sex
partners, increasing their risk of infection.  Some
of these partners may be women who have
become commercial sex workers because of
poverty, and they too are highly vulnerable to
infection.  Migrant workers may carry the
infection back to their wives when they return
home.  Long distance truck drivers, and drivers of
“taxis,” who transport Africans long distances by
car, are probably also key agents in spreading
HIV.
Some behavior patterns in Africa may also be
affecting the epidemic.  In explaining the  fact that
young women are infected at a higher rate than
young men, Peter Piot, the Executive Director
UNAIDS, has commented that “the unavoidable
conclusion is that girls are getting infected not by
boys but by older men,” who are more likely than
young men to carry the disease.   (UNAIDS press
release, September 14, 1999.)  A researcher in a
UNAIDS project studying the differential rate of infection added that “Young (women’s) lives
are being cut short through sex which is all too often forced, coerced, or ‘bought’ with sugar-
daddy gifts.”  Many believe that the infection rate among women generally would be far lower
if women’s rights were more widely respected in Africa and if women exercised more power
in political and economic affairs.  (For more on these issues, see Helen Epstein, “AIDS: the
Lesson of Uganda,” New York Review of Books, July 5, 2001.)  
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The breakdown in social order and social norms caused by armed conflict could also be
contributing to the African epidemic.  Conflict, which has afflicted many sub-Saharan
countries for years, is typically accompanied by numerous incidents of violence against
women, including rape, carried out by soldiers and guerrillas.  Such men are also  more likely
to resort to commercial sex workers than those living in a settled environment.
Some observers believe that the spread of AIDS in Africa could have been slowed if
African leaders had been more engaged and outspoken in the struggle against the disease.
President Yoweri Museveni of Uganda, in particular, has won wide recognition for leading
a successful campaign against AIDS in his country.  But many other African leaders have said
or done comparatively little about the epidemic.
President Daniel arap Moi of Kenya, where 13.9% of adults are infected and nearly a
million people have died from AIDS, did not endorse the use of condoms as a preventive until
December 1999.  (Africa News Service, December 23, 1999.)   In South Africa,  many critics
maintain that the current president, Thabo Mbeki, and his government are not treating the
disease with sufficient urgency.  In April 2000, President Mbeki wrote President Clinton and
other heads of state defending dissident scientists who maintain that AIDS is not caused by
the HIV virus.  In March 2001, Mbeki rejected appeals that the national assembly declare the
AIDS pandemic a national emergency.  
The press reported  in September that Mbeki, using outdated and inaccurate statistics
obtained from the Internet, had concluded that HIV/AIDS was not a leading cause of death
in South Africa and had written to the Minister of Health seeking a review of health
expenditure priorities.  Later in the month, the South African government attempted to delay
publication of a South African Medical Research Council report, which found that AIDS is
indeed the leading cause of death, accounting for 40% of mortality among South Africans
aged 15 to 49.  The Council  predicted that South Africa’s death toll from AIDS would reach
a cumulative total of between 5 and 7 million by 2010, when 780,000 people would be dying
annually from the disease.  Life expectancy would fall from 54 years at present to 41 by the
end of the decade, according to the Council. 
  In August 2001, the South African Treatment Action Campaign (TAC) launched a suit
against the South African government, demanding a comprehensive program to prevent
mother-to-child transmission (MTCT) of HIV.  TAC maintains that current MTCT trials
involving 18 pilot projects providing the antiretroviral drug Nevirapine to HIV-positive
pregnant women are inadequate and that 20,000 babies could be saved by a nationwide
program.  The German firm Boerhringer-Ingelheim offers Nevirapine drug free in Africa for
MTCT programs.  South African officials maintain that safety precautions require testing of
Nevirapine and MTCT prevention procedures before launching a nationwide program.  The
Pretoria high court ruled in favor of the TAC in December 2001, giving the government until
March 31, 2002, to present a plan for a comprehensive MTCT program, including counseling,
testing, and treatment.  The government, however, has appealed the decision.
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Social and Economic Consequences
AIDS is having severe social and economic consequences in Africa, and these negative
effects are expected to continue for many years.  A January 2000 Central Intelligence Agency
National Intelligence Estimate on the infectious disease threat, made public in an unclassified
version, forecasts grave problems over the next 20 years.
At least some of the hardest-hit countries, initially in sub-Saharan Africa and later in other
regions, will face a demographic catastrophe as HIV/AIDS and associated diseases reduce
human life expectancy dramatically and kill up to a quarter of their populations over the
period of this Estimate.  This will further impoverish the poor, and often the middle class,
and produce a huge and impoverished orphan cohort unable to cope and vulnerable to
exploitation and radicalization.  (CIA, The Global Infectious Disease Threat and Its
Implications for the United States [http://www.odci.gov], “Publications and Reports”.)
The estimate predicted increased political instability and slower democratic development as
a result of AIDS.  According to the World Bank,
The illness and impending death of up to 25% of all adults in some countries will have an
enormous impact on national productivity and earnings.  Labor productivity is likely to
drop, the benefits of education will be lost, and resources that would have been used for
investments will be used for health care, orphan care, and funerals.  Savings rates will
decline, and the loss of human capital will affect production and the quality of life for years
to come.  (World Bank, Intensifying Action Against HIV/AIDS in Africa.)
In the most severely affected countries, sharp drops in life expectancy are occurring, and
these will reverse major gains achieved in recent decades.  At AIDS2000, the July 2000
international AIDS conference held in Durban, South Africa, Karen Stanecki of the U.S.
Census Bureau reported that AIDS had cut life expectancy in Botswana from 71 years to 39
and in Zimbabwe from 70 years to 38.  Stanecki predicted that South Africa, Zimbabwe, and
Botswana will begin to experience negative population growth in 2003, and that by 2010, life
expectancy at birth will have fallen to about 30 years throughout southern Africa.
According to many reports, AIDS has devastating effects on rural families.  The father
is typically the first to fall ill, and when this occurs, farm tools and animals may be sold to pay
for his care.  As he grows weaker, he will become unable to farm at all; nor will his wife be
able to farm, since she will be devoting her time to nursing him.  The family will be unable to
pay school fees, and in any event, children will likely be kept out of school to perform added
chores at home.  Should the mother also become ill, children may be forced to shoulder
responsibility for the full time care of their parents.  The economic consequences of the
disruption of rural life can be severe, and reduced food production in some areas due to AIDS
has been reported.
AIDS is also being blamed for shortages of skilled workers and teachers in several
countries.  An October 2001 report from Zambia, for example, indicated that AIDS was
killing about 1,000 teachers annually, nearly equal to half of the 2,200 new teachers who
complete their training each year.   Although unemployment is generally high in Africa,
trained personnel are  not readily replaced.  AIDS is claiming many lives at middle and upper
levels of management in both business and government.  
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AIDS may have serious security consequences for much of Africa, since HIV infection
rates in many armies are extremely high.   Domestic political stability could also be threatened
in African countries if the security  forces become unable to perform their duties due to AIDS.
Peacekeeping is also at risk.   South African soldiers  have been widely expected to play an
important peacekeeping role in the Democratic Republic of the Congo (DRC, formerly Zaire)
and perhaps other countries in coming months and years, but estimates of the infection rate
in the South Africa army run from 17% to 40%, with higher rates reported for units based in
heavily infected KwaZulu-Natal province.  A December 2001 General Accounting Office
(GAO) report raised questions about the ability of the United Nations to promote AIDS
awareness and reduce risky behaviors in U.N. peacekeeping forces.  (GAO Report GAO-02-
194, U.N. Peacekeeping: United Nations Faces Challenges in Responding to the Impact of
HIV/AIDS on Peacekeeping Operations.) The report also noted that the U.N. faced
difficulties in providing HIV/AIDS assistance to civilians affected by conflict.
Responses to the AIDS Epidemic
Donor governments, non-governmental organizations (NGOs) working in Africa, and
African governments have responded to the AIDS epidemic primarily by attempting to reduce
the number of new HIV infections, and to some degree, by trying ameliorate the damage done
by AIDS to families, societies, and economies.  A third possible response – treatment of
AIDS sufferers with medicines that can result in long-term survival – has not been widely
used in Africa, largely due to cost, although some treatment is now being offered at private
clinics or through programs offered by a few large employers.  Demands for large-scale
treatment are mounting in Africa, and  are drawing support from outside the continent among
AIDS activists and others concerned for the region’s future.   An effective vaccine could offer
a permanent solution to the African AIDS crisis, but progress in vaccine development has
been slow.  (For more information on the international response to the epidemic, see CRS
Report RL30883, Africa: Scaling Up the Response to the HIV/AIDS Pandemic.)
Efforts to reduce the number of AIDS infections have focused on increasing AIDS
awareness among Africans.  Programs and projects aimed at combating the disease typically
provide information on how the disease is spread – and on how it can be avoided – through
the media,  posters, lectures, and skits.   Donor-sponsored voluntary counseling and testing
(VCT) programs, where available, enable African men and women to learn their HIV status.
Those testing positive are typically referred to support groups and advised on ways to protect
others from contracting the disease; while the majority testing negative are counseled on
behavior changes that will keep them HIV-free.  USAID is currently supporting VCT centers
in 10 African countries.  AIDS awareness programs can be found in many African schools and
increasingly in the workplace, where employers are recognizing their interest in reducing the
infection rate among their employees.   Many projects aim at making condoms readily
available and on providing instruction in condom use.  USAID is a major provider of
condoms in Africa.  Pilot projects have had success in reducing mother-to-child transmission
by administering the anti-HIV drug AZT or Nevirapine, during birth and early childhood.  
Church groups and humanitarian organizations have helped Africa deal with the
consequences of AIDS by setting up programs to provide care and education to orphans.  The
Farm Orphan Support Trust in Zimbabwe tries to keep sibling orphans together and in a
family living situation; the Salvation Army sponsors a pilot, community-based, orphan support
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program in Zambia, providing education and health care to vulnerable children.  (Report on
the Presidential Mission on Children Orphaned by AIDS.)  A United Nations study has found
that community-based organizations, sometimes with the support of NGOs, have emerged to
supply additional labor, home care for the sick, house repair, and other services to AIDS-
afflicted families. (UNAIDS, A Review of Household and Community Responses to the
HIV/AIDS Epidemic in Rural Areas of Sub-Saharan Africa, 1999.)
Public-private partnerships have also become an important vehicle for responding to the
African AIDS pandemic.  The Bill and Melinda Gates Foundation has been a major supporter
of vaccine research and a variety of AIDS programs undertaken in cooperation with African
governments and donors.   The Rockefeller Foundation, working with UNAIDS and others,
has sponsored programs to improve AIDS care in Africa, and both Bristol-Myers Squibb and
Merck and Company, together with the Gates Foundation and the Harvard AIDS Institute,
have undertaken programs with the Botswana government aimed at improving the country’s
health infrastructure.   
USAID estimates that in FY2000, all donors and lending agencies, together with African
governments, spent approximately $500 million in combating AIDS, but donors have
committed to scaling up the response.  On July 23, 2000,  leaders at the G-8 world economic
summit in Okinawa pledged to reduce the number of young people infected by the HIV virus
by 25%.  The World Health Organization estimated that this pledge, and G-8 pledges to
attack malaria and tuberculosis as well, would cost at least $5 billion per year for 5 years.
The World Bank, on September 12, 2000, made an initial commitment of $500 million to a
Multi-Country HIV/AIDS Program (MAP) for Africa.  The MAP, designed to be both
flexible and rapidly disbursing, according to the Bank, will help fund HIV/AIDS prevention,
care, and treatment programs in countries that have developed a strategic approach to
combating the epidemic and that met certain other conditions.  Nonetheless, on December 9,
2001,  Peter Piot, executive director of the Joint United Nations Program on HIV/AIDS
(UNAIDS), told an international AIDS conference in Burkina Faso  that assistance to fight
HIV/AIDS in sub-Saharan Africa should be increased “many-fold,” and that the region
requires $4.6 billion per year to confront the pandemic.
Global Fund
African heads of state, meeting in Abuja, Nigeria, issued a statement on April 27, 2001,
declaring AIDS a continental emergency, pledging to spend 15% of their annual budgets on
health and urging donors to create a $5 billion to $10 billion Global AIDS Fund.  U.N.
Secretary General Kofi Annan subsequently asked for the creation of an international “war
chest” of $7 billion to $10 billion per year, primarily to fight HIV/AIDS but also to combat
tuberculosis and malaria. 
On May 11, 2001, President Bush, speaking at the White House in an appearance with
Annan and Nigeria’s President Olusegun Obasanjo, announced that the United States would
make a “founding contribution” of $200 million.    The G-8 summit of industrialized nations,
held in Genoa, July 20-22, endorsed the proposed fund and affirmed that members were
committed to making it operational by the end of 2001.  Secretary General Annan  appointed
Dr. Chrispus Kiyonga, former Minister of Health in Uganda, to chair a transitional working
group charged with negotiating the terms for establishing the Fund.   The transitional working
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group included over 40 representatives of governments, non-governmental organizations,
U.N. agencies, foundations, and the private sector.
The Global Fund, which describes itself as an “independent, public-private partnership,”
convened its first Board of Directors meeting in Geneva, Switzerland, where the Fund is
headquartered, on January 28-29.  The Board solicited the first round of grant proposals from
“country partners,” which are to be teams made up of government, non-governmental
organizations, and the private sector; the first grants are expected to announced on April 25,
2002.  Pledges to the Fund from all donors total $1.9 billion.  
The United States has pledged $500 million to the Fund, and to date, Congress has made
available a total of $300 million of this pledge. (See CRS Report RS21114, HIV/AIDS:
Appropriations for Worldwide Programs in FY2001 and FY2002).  The Administration has
requested that the additional $200 million be appropriated in the FY2003 appropriations.  The
funds would come equally from the Foreign Operations Appropriations and from the
appropriations funding the Department of Health and Human Services.  (See CRS Report
RS21181, HIV/AIDS International Programs: FY2003 Request and FY2002 Spending.)




The Global Fund to Fight AIDS, Tuberculosis, and Malaria: 
[http://www.globalfundatm.org]
International AIDS Vaccine Initiative: [http://www.iavi.org]
International Association of Physicians in AIDS Care: [http://www.iapac.org/]
Kaiser Daily HIV/AIDS Report: [http://report.kff.org/aidshiv/]
UNAIDS: [http://www.unaids.org/]
USAID: [http://www.usaid.gov/], click on “Health.”
World Bank: [http://www.worldbank.org/], click on “Topics.”
Effectiveness of the Response
The response to AIDS in Africa has had some successes, most notably in Senegal,
mentioned above, and in Uganda, where the rate of infection among pregnant women in urban
areas fell from 29.5% in 1992 to 11.25% in 2000 (UNAIDS, AIDS Epidemic Update,
December 2001).  The Uganda government sponsors an active AIDS awareness program that
openly advocates the use of condoms.   HIV prevalence among young urban women in
Zambia has also reportedly fallen, and UNAIDS  indicates that urban sexual behavior patterns
may be changing in ways that combat the spread of HIV.  Despite some success stories,
however, available evidence indicates that the epidemic is deepening in most of Africa.  
The December 2000 UNAIDS update on the AIDS epidemic estimated that there had
been 3.8 million new HIV infections in Africa in 2000 as compared to 4 million in 1999, and
suggested that the decrease could in part reflect the success of prevention programs in some
countries.  The December 2001 update recorded a further decline, to 3.4 million new
infections in 2001.    The 2000 report also noted, however, that the decline in new infections
could result partly from the fact that  many of the most vulnerable, sexually active people had
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already been infected  in prior years.  In any event, citing populous Nigeria, where HIV
infection is believed to be spreading, the report warned that the epidemic could still take off
in countries with comparatively low infection rates.  Some also note that 3.4 million new
infections, though fewer than in preceding years, still represent an extraordinarily rapid spread
of a highly destructive disease.
Experts point out  that there are a number of barriers to a more effective AIDS response
in Africa, such as cultural norms that make it difficult for many government, religious, and
community leaders to acknowledge or discuss sexual matters, including sex practices,
prostitution, and the use of condoms.  However, experts continue to advocate AIDS
awareness and AIDS amelioration as essential components of the response to the epidemic.
Indeed, there is strong support for an intensification of awareness and amelioration efforts,
as well as adaptations to make such efforts more effective.  With respect to amelioration,
UNAIDS has recommended  that donors find ways to strengthen those indigenous support
institutions that are already helping AIDS victims and their families.  (A Review of Household
and Community Responses.)   There is also support for a stronger focus on treatment of non-
HIV sexually-transmitted infections, which studies show can dramatically lower the rate of
HIV transmission.  
The lives of infected people could be significantly prolonged and improved, some
maintain, if more were done to identify and treat the opportunistic infections, particularly
tuberculosis, that typically accompany AIDS.  Millions of Africans suffer dual infections of
HIV and TB, and the combined infection dramatically shortens life.   Tuberculosis can be
cured by treatment with a combination of medications over several months, even in HIV-
infected patients.  However, according to the World Health Organization, Africans often
delay seeking treatment for TB or do not complete the course of medication (Global
Tuberculosis Control: WHO Report 1999, Key Findings), contributing to the high incidence
of death among those with dual infections.  Pfizer Corporation has signed an agreement with
South Africa to donate the anti-fungal Diflucan (fluconazole) for treating AIDS-related
opportunistic infections, including cryptococcal meningitis, a dangerous brain inflammation.
On December 1, 2001, Pfizer announced that it would sign memoranda of understanding on
donating fluconazole with six other African countries.  UNAIDS and the World Health
organization recommended on April 5, 2000, that Africans infected with HIV be treated with
an antibiotic/sulfa drug combination known by the trade name Bactrim in order to prevent
opportunistic infections.  Studies indicate that the drug could reduce AIDS death rates at a
cost of between $8 and $17 per year per patient.
AIDS Treatment Issues
Access for poor Africans to costly combinations of AIDS medications or
“antiretrovirals” (ARVs) is perhaps the most contentious issue surrounding the response to
the African epidemic today.  Administered in a treatment regimen known as HAART – highly
active antiretroviral therapy – these drugs can return AIDS victims to normal life and lead to
long-term survival rather than early death.  Such treatment has proven highly effective in
developed countries, including the United States, where AIDS, which had been the eighth
leading cause of death in 1996 no longer ranked among the 15 leading causes by  1998.  (U.S.
Department of Health and Human Services Press Release, October 5, 1999.)
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Advocates of making HAART  widely available in Africa argue that the therapy would
keep parents alive, slowing the growth in the number of AIDS orphans; and keep workers,
teachers, civil servants, and managers alive as well, thus reducing the economic impact of the
epidemic.  Moreover, proponents argue, treatment will strengthen prevention efforts, since
the possibility of treatment will create strong incentives for participation in VCT programs.
Someone who enters treatment and is receiving regular medical attention, many believe, will
be more likely to behave in ways that  minimize the risk of spreading HIV.  Some also see a
moral obligation to try to save lives when the medications for doing so exist.
The high cost of HAART treatments, however, has been regarded as the principal
obstacle to offering the therapy on a large scale in Africa, where most victims are poor and
lack health insurance.  The cost of administering HAART was once estimated at between
$10,000 and $15,000 per person per year.  On May 11, 2000, five major pharmaceutical
companies announced that they were willing to negotiate sharp reductions in the price of
AIDS drugs sold in Africa.  UNAIDS launched a program in cooperation with the
pharmaceutical companies to boost treatment access and, in June 2001, reported that 10
African countries had reached agreement with manufacturers.  The agreements significantly
reduced prices in exchange for health infrastructure improvements to assure that ARVs are
administered safely.  Patented AIDS medications are now  reportedly becoming available in
several African countries, at prices ranging from a few hundred dollars to just over $1000 per
patient per year, for a three-drug treatment comparable to that available in developed
countries.  Private clinics in some African cities are now offering HAART, and Uganda as
well as Cote d’Ivoire are providing treatment in publicly-funded programs to several hundred
patients.  Nonetheless, Harvard expert Dr. Howard Hiatt estimated in December 2001 that
no more than 25,000 Africans were receiving treatment.  (“Learn from Haiti,” New York
Times, December 6, 2001).  A Nigerian program to treat 15,000 AIDS patients with generic
antiretrovirals imported from India has been slow to begin, reportedly due to organizational
problems, and only a few hundred patients are currently being treated. (Africa News, April
5, 2002.)
Harvard University faculty released a “consensus statement” on April 4, 2001,
maintaining that objections to widespread treatment of HIV-infected people in low-income
countries with antiretroviral drugs were not valid.  The statement called for an initial effort
to treat at least one million AIDS patients in Africa within 3 years.
The degree to which Africa’s poorly developed health infrastructure prevents the wider
availability of HAART is controversial.  AIDS activists believe that millions of Africans could
quickly be given access to AIDS drugs.  Others maintain that African supply channels cannot
make the drugs consistently available to millions of patients and that regular monitoring of
patients by medical personnel is not possible in much of the continent.  Monitoring is
necessary, they maintain, to deal with side effects and to adjust medications if drug resistance
emerges.  Many fear that if the drugs are taken irregularly, resistant HIV strains will emerge
that could cause untreatable infections worldwide. 
AIDS activists also advocate “parallel imports” of drugs and “compulsory licensing” by
African governments to lower the price of patented medications.  Through parallel importing,
patented pharmaceuticals could be purchased from the cheapest source, rather than from the
manufacturer; while under “compulsory licensing,” an African government could order a local
firm to produce a drug and pay a negotiated royalty to the patent holder. 
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Although both parallel imports and compulsory licensing are permitted under Agreement
on Trade-Related Aspects of Intellectual Property Rights (TRIPS agreement) of the World
Trade Organization agreement for countries facing national emergencies, U.S. officials once
strongly opposed such measures on grounds that they could lead to infringements of
intellectual property rights.   Advocates for the pharmaceutical companies argued that parallel
importing and compulsory licensing could reduce profits, and that this would hinder the ability
of manufacturers to conduct research on new drugs, including drugs that might be even more
effective against HIV.  A third view has been that some combination of subsidization, price
reduction, and local manufacturing might be found that would make the drugs much more
widely available while maintaining drug company revenues through the sheer volume of
African sales.  
On May 10, 2000, President Clinton issued an executive order stating that the United
States would not seek to prevent sub-Saharan countries from promoting access to HIV/AIDS
pharmaceuticals or medical technologies consistent with the World Trade Organization’s
TRIPS agreement.  On February 22, 2001, an official of the U.S. Trade Representative’s
office said the Bush Administration was not considering any change in current “flexible
policy” on this issue.  On November 14, 2001, a ministerial level meeting of the World Trade
Organization in Doha, Qatar, approved a declaration stating that the TRIPS agreement should
be implemented in a manner supportive of promoting access to medicines for all.  The
declaration affirmed the right of countries to issue compulsory licenses and gave the least
developed countries until 2016 to implement TRIPS.  The question of whether poor countries
should be permitted to import generic copies of patented drugs was left for further study.  
Although the Doha declaration drew broad praise, some AIDS activists criticized it for
not permitting generic imports – cheap copies of patented medications.  Some in the
pharmaceutical industry, on the other hand, expressed concern that the declaration was too
permissive and might eventually open the way to such imports.  Others, however, argued that
the declaration would have little practical impact, since most AIDS drugs are not actually
patented in many of the countries most heavily affected by the epidemic.  From this
perspective, poverty rather than patents is the principal obstacle to drug access in Africa.
(See Amir Attaran and Lee Gillespie-White, “Do Patents for Anti-retroviral Drugs Constrain
Access to AIDS Treatment in Africa?” Journal of the American Medical Association,
October 17, 2001.)  
The United Nations convened a General Assembly Special Session (UNGASS) on
HIV/AIDS on June 25-27 in New York.  Much of the debate at the session centered on the
issue of whether large-scale treatment with anti-retroviral drugs could be provided in Africa.
The Special Session concluded with passage of a resolution emphasizing the need for
“widespread and effective prevention,” but “recognizing that care, support, and treatment can
contribute to effective prevention.” 
U.S. Policy
A July 2000 Washington Post article called into question the adequacy and timeliness
of the early U.S. response to the HIV/AIDS threat in Africa.  (Barton Gellman, “The Global
Response to AIDS in Africa: World Shunned Signs of Coming Plague.”  Washington Post,
July 5, 2000).  Nonetheless, U.S. concern did begin to mount during the 1980s, as the severity
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of the epidemic became apparent.  In 1987, in acting on the FY1988 foreign operations
appropriations bill, Congress earmarked funds for fighting AIDS worldwide, and House
appropriators noted that in Africa, AIDS had the potential for “undermining all development
efforts” to date (H.Rept. 100-283).  In subsequent years, Congress supported AIDS spending
at or above levels requested by the executive branch, either through earmarks or report
language.
USAID states that it has been the global leader in the international response to AIDS
since 1986, not only by supporting multilateral efforts  but also by directly sponsoring
regional and bilateral programs aimed at combating the disease.  (USAID, Leading the Way:
USAID Responds to HIV/AIDS, September 2001).   The Agency has sponsored AIDS
education programs; trained AIDS educators, counselors, and clinicians; supported condom
distribution; and sponsored AIDS research.  USAID claims several successes in Africa, such
as helping to reduce HIV prevalence among young Ugandans and to prevent an outbreak of
the epidemic in Senegal; reducing the frequency of sexually transmitted infections in several
African countries; sharply increasing condom availability in Kenya  and elsewhere; assisting
children orphaned by AIDS; and sponsoring the development of useful new technologies,
including the female condom.  USAID reports that it spent a total of $51 million on fighting
AIDS in Africa in FY1998 and $63 million in FY1999 (Leading the Way, 121).  In addition,
some spending by the Department of Health and Human Services was going toward HIV
surveillance in Africa and other Africa AIDS-related efforts.
 As the severity of the epidemic continued to deepen, many of those concerned for
Africa’s future, both inside and outside government, came to feel that more should be done.
On July 19, 1999, Vice President Gore proposed $100 million in additional spending for a
global LIFE  (Leadership and Investment in Fighting an Epidemic) AIDS initiative to begin
in FY2000, with a heavy focus on Africa.  Funds approved during the FY2000 appropriations
process supported most of this initiative.
On June 27, 2000, the Peace Corps announced that all volunteers serving in Africa
would be trained as AIDS educators and that 200 former volunteers would be sent to Africa
through the Crisis Corps to work in AIDS care and prevention.  Fifty new volunteers would
work exclusively on AIDS-related projects in eastern and southern Africa.
Bush Administration
The Bush Administration has continued to support increases in HIV/AIDS spending for
Africa, and the President has appointed a cabinet level task force, co-chaired by Secretary of
State Colin Powell and Secretary of Health and Human Services Tommy Thompson, to
develop and coordinate HIV/AIDS policy.  An interagency policy coordinating committee
headquartered at the White House has been established to back up the task force.   Moreover,
as noted above, President Bush made the “founding pledge” of $200 million to the global
Fund, and U.S. pledges to the Fund now total $500 million.
  Many support a larger U.S. contribution to the Global Fund, and bills currently before
Congress would provide considerably more than has been pledged.  (See for example, H.R.
2069, described in the Legislation section, or S. 1936 listed under Legislative Action.)
Others argue, however, that the Administration has taken only the first steps in what could
turn out to be a major long-term commitment.  At the same time, some concern has been
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expressed about the Administration’s focus on the Global Fund, as some observers worry that
the Fund  may be diverting attention and support from the bilateral programs of USAID and
the CDC.  Many regard these programs as more effective than those of other organizations
and agencies in coping with the African pandemic.  In response, others argue that by
supporting the Fund, the United States sets an example that helps to “leverage” contributions
from other donors, thus attracting new resources to the fight against AIDS. 
On June 25, 2001, Secretary of State Powell told the United Nations General Assembly
Special Session on HIV/AIDS that the global response to the pandemic had been “woefully
inadequate” to date.  Noting the U.S. support  for the Global Fund, however, Powell affirmed
that “more will come from the United States as we learn where our support can be most
effective.”  The Secretary of State, also noting U.S. bilateral HIV/AIDS programs and
vaccine research, called for an integrated approach to the pandemic, emphasizing prevention
but also including treatment, orphan care, affordable drugs, and health infrastructure.




USAID 109 144 183
CDC 34 86 89
DOD 0 5 14
DOL 0 3 6
Total 143 238 292
Table 1, which reviews AIDS spending in Africa since FY2000, indicates that spending
through programs of USAID and the Centers for Disease Control (CDC) of the Department
of Health and Human Services has increased significantly.  In addition, the Defense
Department (DOD) has undertaken an HIV/AIDS education program with African armed
forces.  (See CRS Report RL30761, HIV-1/AIDS and Military Manpower Policy.  The
amount reported in Table 1 for this program in FY2002 is the appropriated amount.)
Meanwhile the Department of Labor (DOL) has launched a program that supports AIDS
education in the African workplace.   USAID is targeting three heavily affected African
countries – Kenya, Uganda, and Zambia – for a rapid scale up in HIV/AIDS activities
intended to show measurable results in one to two years.  Ten African countries have been
identified for “intensive focus” to reduce prevalence rates as well as mother-to-child
transmission and to increase support services for people living with or affected by AIDS
within 3 to 5 years.  USAID will maintain basic programs, including technical assistance,
training, and provision of commodities in eight other African countries.  Additional U.S. funds
reach Africa indirectly through the AIDS programs of the United Nations, including the




The Bush Administration’s proposed FY2003 budget seeks $500 million in Development
Assistance for HIV/AIDS programs worldwide, and of this amount, $250.4 million would be
spent in Africa.  In addition, the Administration is requesting $2 million in Foreign Military
Financing to complement the Defense Department’s AIDS prevention education program  for
African armed forces.  However, funds have not been requested for the Defense Department
program itself.   Africa-specific funding levels for other programs have not yet been
determined, but substantial increases seem unlikely.  For CDC HIV/AIDS activities
worldwide,  the Administration is requesting $143.8  million, the same level as appropriated
for FY2002.  The  $200 million request for the Global Fund is also the same as the FY2002
level.  No funds have been requested for the Department of Labor’s AIDS in the Workplace
program.
The General Accounting Office released a report in March 2001 calling on USAID to
develop better measures for evaluating the effectiveness of its HIV/AIDS programs in Africa.
(GAO Report GAO-01-449, U.S. Agency for International Development Fights AIDS in
Africa, but Better Data Needed to Measure Impact.)  In its response, USAID indicated that
it had improved monitoring and evaluation and was using standardized indicators that it had
published in a handbook for use in the field.
The Africa Subcommittee of the Senate Foreign Relations Committee held a hearing on
HIV/AIDS on February 14, 2002.  Dr. E. Anne Peterson, Assistant Administrator for Global
Health at the U.S. Agency for International Development, testified that preventing new
infections remained the most urgent priority.  Peterson added that USAID would be launching
four treatment sites in Africa in 2002 to provide “critically needed answers” to the challenges
of providing antiretroviral therapy.  Harvard Professor Jeffrey Sachs, coordinator of a recent
World Health Organization study on macroeconomics and health, argued that with “concerted
financial support” treatment could be provided on “a greatly enlarged scale.” 
Legislative Action
In August 2000, the Global AIDS and Tuberculosis Relief Act of 2000 (P.L. 106-264)
became law.  This legislation authorized funding for fiscal years 2001 and 2002 for a
comprehensive, coordinated, worldwide HIV/AIDS effort under USAID, not less than 65%
to be available through non-governmental organizations, including religious-affiliated
organizations, not less than 20% to be available for a multi-donor strategy to address the
support and education of orphans in sub-Saharan Africa, and not less than 8.3% for the
prevention of  mother to child transmission.   In 2001, a number of bills were introduced with
international or Africa-related HIV/AIDS related provisions.  These include:
H.R. 684 (Millender-McDonald), to authorize assistance for mother-to-child HIV/AIDS
transmission prevention efforts. 
H.R. 933 (Waters), Affordable HIV/AIDS Medicines for Poor Countries Act.
H.R. 1185 (Lee), Global Access to HIV/AIDS Medicines Act of 2001.
H.R. 1269 (Crowley), Global Health Act of 2001.
H.R. 1567 (Lee), to encourage the provision of multilateral debt cancellation for countries
eligible to be considered for assistance under the Heavily Indebted Poor Countries
(HIPC) Initiative or heavily affected by HIV/AIDS, and for other purposes. 
H.R. 1642 (Waters), Debt Cancellation for the New Millennium Act.
H.R. 1690 (Waters), Export-Import Bank HIV/AIDS Medicine Access Promotion Act.
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H.R. 2104 (Eddie Bernice Johnson), to amend the Foreign Assistance Act of 1961 to
authorize the provision of education and related services to law enforcement and military
personnel of foreign countries to prevent and control HIV/AIDS and tuberculosis. 
H.R. 2209 (Bereuter), World Bank AIDS Trust Fund Amendments Act of 2001.
H.R. 2839 (Millender-McDonald), Peace Corps HIV/AIDS Training Enhancement
Appropriations Act for Fiscal Year 2002.
S. 463 (Feinstein), Global Access to AIDS Treatment Act of 2001.
S. 895 (Kerry), Vaccines for the New Millennium Act of 2001.
S. 1032 (Frist),  International Infectious Diseases Control Act of 2001.
S. 1120 (Boxer), Global AIDS Research and Relief Act of 2001.
S. 1230 (Frist/Clinton), Global Leadership in Developing the Expanded Response Act, or the
“GLIDER Act.”
S. 1752 (Corzine), Microbicide Development Act of 2001.
S. 1936 (Durbin), Global Coordination of HIV/AIDS Response Act
Bills that have been reported out of committee or received floor action are detailed
below, under Legislation.  For information on appropriations for HIV/AIDS programs in
FY2002, see  CRS Report RS21114, HIV/AIDS: Appropriations for Worldwide Programs
in FY2001 and FY2002.
LEGISLATION
H.Con.Res. 102 (Leach)
Hunger to Harvest: A Decade of Support for Africa.  States sense of Congress that
within 90 days the President should submit a report setting forth a five-year strategy, and a
ten year strategy, to reverse hunger and poverty in Africa; emphasis should be on health,
among other objectives, including HIV/AIDS.  Introduced in the House on April 4, 2001, and
referred to the Committee on International Relations.  Marked up on November 1 and passed
under a suspension of the rules (400-9), December 5.  Received in the Senate, December 6.
Passed the Senate by unanimous consent, March 8, 2002.
 
H.R. 1646 (Hyde)
Department of State Authorization.   Authorizes up to $1 million for HIV/AIDS research
and mitigation strategies in a Border-Less World academic program of the Fulbright
Academic exchange program; states the sense of Congress that  U.S. officials should urge the
United Nations to adopt an HIV/AIDS mitigation strategy as a component of U.N.
peacekeeping operations; and that the Secretary of State should establish an international
HIV/AIDS intervention, mitigation, and coordination task force.  Introduced on May 4, 2001;
referred to the Committee on International Relations.  Marked up and ordered reported, May
2; report filed (H.Rept. 107-57).  Passed the House, May 16.  Received in the Senate and
referred to the Committee on Foreign Relations, May 17, 2001.
H.R. 2069 (Hyde)
Global Access to HIV/AIDS Prevention, Awareness, Education, and Treatment Act of
2001.  States the sense of Congress that the United States should provide additional funds for
multilateral programs and efforts to combat HIV/AIDS, including programs that make
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available pharmaceuticals and diagnostics for HIV/AIDS therapy in sub-Saharan Africa; and
that programs to help AIDS orphans as well as micro-enterprise programs for HIV/AIDS
affected families should be expanded; amends the Foreign Assistance Act of 1961 (P.L. 87-
195) to state that HIV/AIDS assistance should include prevention (including assistance
through faith-based organizations), treatment, monitoring, and related activities; requires an
annual report on USAID HIV/AIDS activities; authorizes $560 million for these activities in
each of fiscal years 2002 and 2003; requires USAID to assist sub-Saharan and other
developing countries to procure and distribute HIV/AIDS pharmaceuticals, including
antiretrovirals, and authorizes $50 million for this purpose; states that the President shall
establish an inter-agency task force to coordinate international HIV/AIDS activities;
establishes a permanent Global Health Advisory Board to assist in the development and
implementation of international health programs; authorizes $750 million in FY2002 for
contributions to a global health fund or other  multilateral efforts to prevent and treat
HIV/AIDS.  Introduced on June 6, 2001; referred to the Committee on International
Relations.  Amendment in the nature of a substitute marked up and approved by the House
International Relations Committee, June 27, 2001.  Reported (H.Rept. 107-137) July 12.
Passed the House by a voice vote under a suspension or the rules, December 11.  Received
in the Senate and referred to the Committee on Foreign Relations, December 12, 2001.
